Results 81 to 90 of about 34,483 (232)

Long‐Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long‐Term Safety Extension

Alimentary Pharmacology &Therapeutics, EarlyView.
In the POISE open‐label extension, patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid received long‐term obeticholic acid (OCA) treatment. Findings demonstrated a safety profile consistent with the known characteristics of OCA, with no unexpected safety signals, while supporting sustained efficacy ...
Christopher L. Bowlus, Frederik Nevens, Kris V. Kowdley, Alan Bonder, Thomas Capozza, Jing Li, Radhika Nair, Michael Trauner, David E. Jones   +8 more
wiley   +1 more source

Minimal residual disease–guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype

British Journal of Haematology, EarlyView.
Minimal residual disease (MRD)–guided ibrutinib and venetoclax (IVen) achieved durable remissions and high undetectable MRD (uMRD) rates in patients with high‐risk chronic lymphocytic leukaemia (CLL). Compared with historical ibrutinib monotherapy, IVen was associated with improved progression‐free and overall survival despite presence of complex ...
Maria Kislova, Elena Dmitrieva, Elena Naumova, Margarita Pochtar, Svetlana Lugovskaya, Yury Kobzev, Alla Loban, Maria Gladysheva, Tatiana Obukhova, Bella Biderman, Andrey Sudarikov, Egor Volchkov, Maria Ivanova, Vadim Ptushkin, Andrea Visentin, Eugene Nikitin   +15 more
wiley   +1 more source

Epistaxis Rates and Health Care Utilization in Patients With a Ventricular Assist Device

OTO Open
Objective Identify baseline epistaxis rates and epistaxis‐related health care utilization trends in the ventricular assist device (VAD) population.
Eric Rohe, Sarah Schmoker, Kaeli Samson, Kristy Carlson, Jayme Dowdall   +4 more
doaj   +1 more source

First‐In‐Human Study of Mirogabalin (BM2216) Sustained‐Release Tablets: Safety, Tolerability, Pharmacokinetics, Food Effect and Dose Proportionality With Comparison to Mirogabalin Besylate in Healthy Participants

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To characterise the pharmacokinetics (PKs) and safety of BM2216 sustained‐release (SR) tablets after single‐dose oral administration under fasted/fed conditions in healthy participants, assess the effect of food and dose proportionality, and compare the single and multiple‐dose PK of BM2216 SR tablets with mirogabalin besylate tablets to ...
Peiyang Song, Hongtao Zhao, Mingxue Zhu, Lei Wan, Yuan Chen, Zhongping Li, Chengyong Tang   +6 more
wiley   +1 more source

Performing Large‐Scale Genetic Analysis in the Bleeding Disorders Community

Haemophilia, EarlyView.
ABSTRACT Inherited bleeding disorders encompass a diverse group of conditions caused by genetic defects affecting coagulation factors, fibrinogen, von Willebrand factor, or platelet function. Despite major advances in quantitative and functional laboratory assays, a substantial diagnostic gap remains, particularly in patients with mild or atypical ...
Anna R. Blankstein, Sterre P. E. Willems, Saskia E. M. Schols, Rosanna Asselta, Gillian Lowe, Neil V. Morgan, Paula D. James   +6 more
wiley   +1 more source

Epistaxis during the third trimester of pregnancy is associated with blood transfusion a retrospective case–control study

Archives of Gynecology and Obstetrics
Background Epistaxis is common during pregnancy due to physiological changes, yet its clinical significance regarding obstetric outcomes is poorly understood.
Aviad Sapir, Lior Friedrich, Yonathan Osovizky, Yotam Heilig, Oded Cohen, Shay Schneider   +5 more
doaj   +1 more source

Rare Bleeding Disorders and Bleeding Disorder of Unknown Cause: Current Understanding and Recent Developments

Haemophilia, EarlyView.
ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini, Robert Klamroth, Bauke Haisma, Dino Mehic, Saskia E. M. Schols   +4 more
wiley   +1 more source

The XX Factor in Hemophilia: Diagnostic, Therapeutic, and Research Gaps for Women and Girls

Haemophilia, EarlyView.
ABSTRACT Introduction Hemophilia has traditionally been viewed as an X‐linked disorder affecting men and boys, with women and girls labeled as “carriers”, presumed to be clinically unaffected. This paradigm has contributed to under‐recognition, delayed diagnosis, and undertreatment of females with hemophilia‐associated genotypes despite an increasingly
Kelsey Uminski, Ellen Cusano
wiley   +1 more source

Intranasal bleomycin sclerotherapy versus local Avastin® therapy as an adjunct to laser treatment for epistaxis in hereditary hemorrhagic telangiectasia

Discover Medicine
Background Hereditary hemorrhagic telangiectasia is a rare disease of vascular development, often accompanied by severe epistaxis. Multimodality treatment may improve epistaxis control, but the optimal combination of modalities has not yet been ...
Karin P. Q. Oomen, Volkert B. Wreesmann, Benjamin J. Waner, Stefan Waner, Milton Waner, Teresa M. O   +5 more
doaj   +1 more source

DDAVP Challenges in 170 Children With von Willebrand Disease: Response Classification Varies According to Criteria Used

Haemophilia, EarlyView.
ABSTRACT Introduction Individuals diagnosed with types 1/1C/2A/2M von Willebrand disease (VWD) typically undergo a desmopressin (DDAVP) challenge to assess therapeutic benefit. This involves measuring von Willebrand factor antigen (VWF:Ag), activity (VWF:Act; VWF:RCo/VWF:GPIbM/VWF:Ab), and coagulant factor VIII (FVIII:C) levels 0 (pre), 1, and 4‐h post‐
Michael Shu, Caroline Malcolmson, Amanda Fregonas, Tristan E. Knight, Margaret L. Rand, Cindy Wakefield, Vanessa Bouskill, Manuel Carcao   +7 more
wiley   +1 more source